Jérôme Fayette

Also affiliated with Université de Lyon, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer”.

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

New England Journal of Medicine(2015)10.1056/nejmoa1507643

N/A

1.4DataRank · unranked

9414 citations

Luis Paz-Ares, Diane P Holder, David R. Spigel, Martin Steins, Neal E. Ready +38 more

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.08.22.457244

N/A

0DataRank · unranked

2 citations

Jonathan Zorea, Sankar Jagadeeshan, Avital Beeri Shnerb, Jebrane Bouaoud, Lucas Michon +24 more

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2021-003917

N/A

0DataRank · unranked

70 citations

Jonathan Zorea, Sankar Jagadeeshan, Avital Beeri Shnerb, Sooraj Mathukkada, Jebrane Bouaoud +27 more